NANTES, France--(BUSINESS WIRE)--Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), announces a new research collaboration agreement with premier cancer research hospital, Léon Bérard Cancer Center in Lyon, France, to use artificial intelligence (AI)-based bioanalysis and bioinformatics to identify novel targets in immuno-oncology.
Léon Bérard Cancer Center (CLB) has both a cancer immunotherapy laboratory and translational research laboratory and is recognized as a scientific expert in oncology, particularly in tumor targeting and in the immune environment. Additional resources at CLB include its state-of-the-art bioinformatics platform and biological resource center. Their experience in analyzing and integrating data from The Cancer Genome Atlas (TCGA) allows detailed analysis of clinically relevant targets in populations that could potentially benefit from an innovative therapeutic approach.
This new collaborative immuno-oncology research program will use different patient cohorts and tumor biopsies to identify novel molecular targets associated with the primary and secondary resistance to PD-1/PD-L1 immune checkpoint inhibitors and to validate a strategy of combining drugs based on target expression profile.
The research is based on an artificial intelligence approach jointly developed which will be applied to analyze gene expression in the human tumor microenvironment and the composition of tumor infiltrates. The findings from this collaboration will be used for the selection and validation of innovative targets for early development of new drug candidates from the platform of bispecific fusion proteins targeting PD-1 and innovative targets (BiCKI®).
“We are very excited to begin a new collaboration with an expert team and the CLB, a premier cancer research center. The goal of this partnership is to identify and validate new targets that will help streamline the development of new treatment approaches for cancer, especially in difficult to treat tumors,” said Alexis Peyroles, chief executive officer of OSE Immunotherapeutics.
Professor Jean-Yves Blay, M.D., Ph.D., director of the Léon Bérard Cancer Center commented, "Our AI approach combined with our translational and immunological research platforms will enable us to analyse tumor immune parameters and to identify potential new pathways to address unmet needs for cancer patients. This partnership brings together top experts in oncology research and translational science with the hopes of rapidly advancing the discovery of first-class treatment options for cancer patients. We are very pleased to work in collaboration on this cutting-edge research with OSE Immunotherapeutics."
About the Léon Bérard Center
The Centre Léon Bérard (CLB) is
part of the twenty French Comprehensive Cancer Centres in France,
providing a global management of cancer patients on a unique area, from
diagnosis to treatment and beyond. The Centre is a regional, national
and international recognized reference cancer Centre assigned with three
essential missions: Care, Research and Education and is willing to
continuously improve the quality and accessibility of care for cancer
patients.
More than 34,000 patients are received each year, on
consultations or exams and 6,000 new cancer cases are diagnosed.
The
CLB has technical and treatment facilities (operating room, radiation
therapy centre, medical imaging departments, pathology and nuclear
medicine departments).
The bench-to-bedside process is one of the
strength of the Centre Léon Bérard
The Centre Léon Bérard develops
an excellence and multidisciplinary research, in association with the
cares carried out on site and institutional and private partners.
The
foundations of this development lay in the medical and scientific
project. The CLB aims to reinforce the bench-to-bedside process by
facilitating translational research to help innovation and speed-up its
access to patients for diagnoses and therapies.
Clinical research
has been certified ISO 9001 since 2013 and is thus one of the strength
of the Centre.
As a result, more than 19% of patients were included
in clinical trials in 2017.
At the Centre Léon Bérard 1,700 persons
work in cares, research, education and supportive care (200 physicians,
500 researchers, 600 caregivers) .
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a
clinical-stage biotechnology company focused on developing and
partnering therapies to control the immune system for immuno-oncology
and autoimmmune diseases. The company has a diversified first-in-class
clinical portfolio consisting of several scientific and technological
platforms including neoepitopes and agonist or antagonist monoclonal
antibodies, all ideally positioned to fight cancer and autoimmune
diseases. The most advanced therapeutic-candidate, Tedopi®,
is a proprietary combination of 10 neo-epitopes aimed at stimulating
T-lymphocytes and is currently in Phase 3 development in non-small cell
lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and
anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination
with checkpoint inhibitor Opdivo®. FR104 (an anti-CD28 mAb) has
successfully completed Phase 1 testing and has potential to treat
autoimmune diseases. BI 765063 (OSE-172) (anti-SIRPa monoclonal
antibody) is under a license and collaboration agreement with Boehringer
Ingelheim ; this checkpoint inhibitor has received CTA from French and
Belgian health authorities for a Phase 1 clinical trial in multiple
cancer indications. BiCKI® is a bispecific antibody fusion protein
platform built on the key anti-PD-1 (OSE-279) backbone component and
targeting innovative second targets. OSE-127 (monoclonal antibody
targeting the CD127 receptor, the alpha chain of the interleukin-7
receptor) is partnered with Servier under an option agreement up to the
completion of a Phase 2 clinical trial planned in autoimmune bowel
diseases; in parallel, Servier plans a development in the Sjögren
syndrome. OSE-127 is currently under Phase 1 clinical trial.
Click
and follow us on Twitter
and Linkedln
Forward-looking statements
This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate.
These
forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import.
Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics’
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance.
This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 26 April 2018, including the
annual financial report for the fiscal year 2017, available on the OSE
Immunotherapeutics’ website.
Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date hereof
and does not undertake any obligation to update or revise the
forward-looking information or statements.